Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PG stock price vs INCY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INCY's multiple
Needs Annual EPS, INCY P/E.
Implied fair value · at PG's multiple
Needs Annual EPS, PG P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PROCTER & GAMBLE Co · implied price per share
Reporting currency could not be verified.
INCYTE CORP · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
PG · not enough data.
INCY · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COLGATE PALMOLIVE CO
PG vs CL
KIMBERLY CLARK CORP
PG vs KMB
CHURCH & DWIGHT CO INC /DE/
PG vs CHD
CLOROX CO /DE/
PG vs CLX
Johnson & Johnson
PG vs JNJ
AMGEN INC
PG vs AMGN
GILEAD SCIENCES, INC.
PG vs GILD
VERTEX PHARMACEUTICALS INC / MA
PG vs VRTX
REGENERON PHARMACEUTICALS, INC.
PG vs REGN
BIOGEN INC.
PG vs BIIB
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PG deserves a premium for stability, ROIC, and balance sheet strength, then hold rather than add aggressively because the current price still implies 16.0% downside on the provided P/E valuation and sits well above the DCF range.
On the provided P/E-based valuation, PG’s implied price of $121.38 is 16.0% below the current price of $144.49, suggesting the stock looks overvalued on this framework. However, PG also trades below the upper end of its historical band and well above the DCF range, indicating the market is still paying for durability and quality rather than deep value.
Supporting Metrics
